4-溴-1H-吲唑-3-胺 | 914311-50-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 4-溴-1H-吲唑-3-胺
• 中文别名: 3-氨基-4-溴-1H-吲哚
• 英文名称: 4-bromo-1H-indazol-3-amine
• 英文别名: 4-bromo-3-amino-1H-indazole
• CAS: 914311-50-5
• 化学式: C₇H₆BrN₃
• 分子量: 212.049
• InChiKey: IXXXOIXGQFPLIH-UHFFFAOYSA-N

物化性质

• 熔点：
  142-144℃
• 沸点：
  431.3±25.0 °C(Predicted)
• 密度：
  1.867±0.06 g/cm3(Predicted)
• 溶解度：
  微溶于水。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  应存放在室温、避光且充满惰性气体的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Bromo-1H-indazol-3-amine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Bromo-1H-indazol-3-amine
Ingredient name:
CAS number: 914311-50-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BrN3
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

4-溴-1H-吲唑-3-胺是一种医药中间体，可通过2-氟-6-溴苄腈与98%水合肼在正丁醇中反应制备得到。已有文献报道其可用于制备Bcr-Abl和SRC多靶点抑制剂，并对T315I突变耐药酶表现出良好的活性。

用途

4-溴-1H-吲唑-3-胺可作为原料，用于合成一种新型蛋白激酶抑制剂。这种抑制剂具有针对Bcr-Abl和SRC多个位点的活性，并能有效对抗T315I突变耐药的酶。

制备

将22.0 mmol 2-氟-6-溴苄腈与90.0 mmol 98%水合肼溶解于15 ml正丁醇中，回流搅拌7小时。冷却至室温后，减压浓缩混合物至体积为5 ml。加入适量水，沉淀固体产物。过滤并用水洗涤沉淀，干燥后通过甲醇结晶进一步纯化得到4-溴-1H-吲唑-3-胺。

反应信息

• 作为反应物：
  描述：

  4-溴-1H-吲唑-3-胺 在 potassium phosphate 、 copper(l) iodide 、 N,N-二甲基甘氨酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 264.25h， 生成 tert-butyl 4-{10-[(4R)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxo-1,2-dihydropyrimido[1,2-b]indazol-4-yl}piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] INDAZOLOPYRIMIDINONES AS FIBRINOLYSIS INHIBITORS
  [FR] INDAZOLOPYRIMIDINONES COMME INHIBITEURS DE LA FIBRINOLYSE

  摘要：

  本申请涉及新型取代吲唑吡咯嘧啶酮，其制备方法，以及用于治疗和/或预防疾病的化合物，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者急性和复发性出血的方法，其中出血与从重经期出血、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。

  公开号：

  WO2016173948A1
• 作为产物：
  描述：

  2-氟-6-溴苯腈 在 肼 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 4-溴-1H-吲唑-3-胺
  参考文献：
  名称：

  COMBINATION OF KINASE INHIBITORS AND USES THEREOF

  摘要：

  本发明提供了一种治疗与PI3-激酶a和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，该发明提供了一种治疗与PI3-激酶α和/或受体酪氨酸激酶（RTK）有关的疾病状况的方法。另一方面，提出了一种抑制细胞中Akt（S473）磷酸化的方法。

  公开号：

  US20150030588A1

文献信息

• [EN] COMBINATION OF KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMBINAISON D'INHIBITEURS DE KINASE ET SES UTILISATIONS
  申请人：INTELLIKINE LLC

  公开号：WO2014151147A1

  公开（公告）日：2014-09-25

  The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

  本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面，该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面，提出了一种抑制细胞内Akt（S473）和Akt（T308）磷酸化的方法。本发明还提供了一种有效治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的药物套装。
• 一种嘧啶并吲唑类化合物的合成方法
  申请人：新乡医学院

  公开号：CN109912606B

  公开（公告）日：2021-05-04

  本发明公开了一种嘧啶并吲唑类化合物的合成方法，属于有机合成技术领域。本发明的技术方案要点为：一种嘧啶并吲唑类化合物的合成方法，具体步骤为：将芳香醛类化合物、3‑氨基吲唑类生物和三乙胺溶于溶剂中，再加入NH4I和氧化剂，然后于110‑150℃反应制得目标产物嘧啶并吲唑类化合物。本发明合成过程简单高效，通过无过渡金属催化的一锅串联反应一步直接制得嘧啶并吲唑类化合物，避免了由于多步反应中多种试剂的使用以及对各步反应中间体的纯化处理等引起的资源浪费和环境污染，合成过程操作方便，原料简单，反应条件温和，底物适用范围广，同时以三乙胺为原料极大地降低了生产成本。
• Aerobic α,β-C(sp³)–H Bond Difunctionalization and C–N Bond Cleavage of Triethylamine: Difunctional Ammonium Iodide Enabling the Regioselective Synthesis of 4-Arylpyrimido[1,2-<i>b</i>]indazoles
  作者：Qinghe Gao、Xinya Han、Peiyuan Tong、Zhiang Zhang、Haotian Shen、Yanrong Guo、Suping Bai

  DOI：10.1021/acs.orglett.9b02218

  日期：2019.8.2

  A novel method for the regioselective synthesis of 4-arylpyrimido[1,2-b]indazoles has been developed via the dual C(sp3)–H bond functionalization and C–N bond cleavage of triethylamine. The elusive acyclic enamine intermediates are effectively in situ generated and captured by aromatic aldehydes to form a wide array of tricyclic products from 3-aminoindazoles under the NH4I-mediated aerobic oxidative

  通过三乙胺的双C（sp 3）-H键官能化和C-N键裂解，开发了一种新的区域选择性合成4-芳基嘧啶[1,2- b ]吲唑的新方法。难以捉摸的无环烯胺中间体可在NH 4 I介导的需氧氧化条件下有效地原位生成并被芳族醛捕获，从而形成多种由3-氨基吲唑形成的三环产物。该反应具有容易获得的原料，绿色和经济条件以及有价值的产品的特点。
• Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
  申请人：Ren Pingda

  公开号：US09295673B2

  公开（公告）日：2016-03-29

  The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

  本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面，该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面，提出了一种抑制细胞内Akt（S473）和Akt（T308）的磷酸化的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Intellikine LLC

  公开号：US20150320727A1

  公开（公告）日：2015-11-12

  Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

  本文描述了调节PI3激酶活性的杂环实体、含有这些杂环实体的药物组合物，以及利用这些化学实体治疗与PI3激酶活性相关的疾病和症状的方法。